Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Tissue Regenix Group's Enterprise Value is €12.86 Mil.
Tissue Regenix Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.42 Mil. Therefore, Tissue Regenix Group's EV-to-OCF for today is -30.83.
The historical rank and industry rank for Tissue Regenix Group's EV-to-OCF or its related term are showing as below:
FRA:LSW'
s EV-to-OCF Range Over the Past 10 Years
Min: -48.22 Med: -11.78 Max: 66.18
Current: -30.83
During the past 13 years, the highest EV-to-OCF of Tissue Regenix Group was 66.18. The lowest was -48.22. And the median was -11.78.
FRA:LSW's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.515
vs FRA:LSW: -30.83
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tissue Regenix Group (FRA:LSW) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tissue Regenix Group's PE Ratio (TTM) for today is calculated as:
Tissue Regenix Group's share price for today is €0.07.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Regenix Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tissue Regenix Group EV-to-OCF Related Terms
Tissue Regenix Group EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tissue Regenix Group's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's EV-to-OCF falls into.
Tissue Regenix Group's current Enterprise Value is €12.86 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Regenix Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a EV-to-OCF of -30.83 as of Aug. 12, 2026.
Is Tissue Regenix Group's EV-to-OCF too high?
Tissue Regenix Group's current EV-to-OCF is -30.83. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's EV-to-OCF compare to VRTX and REGN?
Tissue Regenix Group's EV-to-OCF of -30.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Tissue Regenix Group's current EV-to-OCF is -30.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current EV-to-OCF of -30.83. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current EV-to-OCF is -30.83. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current EV-to-OCF is -30.83 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
EV-to-OCF: -30.83
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
